Reply to 'Neutral tumor evolution?' Heide et al. reply -We thank Tarabichi and colleagues 1 for the constructive criticism of our previous work 2 . Their critique has four main points that we address below.
impact of clonal copy number alterations
In our previous study 2 , we assessed the cumulative variant allele frequency (VAF) distribution M(f) over the frequency range f = [0.12,0.24] to restrict our analysis to subclonal variants within a range applicable to the diverse datasets that we considered. Tarabichi and colleagues note that tumors with a tetraploid genome will have an additional 'peak' of clonal mutations at f ~0.25 (mutations in a single allele, Supplementary Fig. 1a ), thus causing incorrect rejection of neutrality ( Supplementary Fig. 1b) . The integration range that we chose was based on a triploid tumor with read depth of 100× , thereby resulting in an upper threshold of 0.26 (Supplementary Methods). Although this procedure is suitable in most cases, it is not suitable for a tetraploid tumor, thus suggesting that the number of tumors consistent with neutral evolution could be larger than we reported. We show how this problem can be avoided by adjusting the range for tetraploid tumors ( Supplementary Fig. 1c ) . We do acknowledge that the 1/f integration method is more accurate when applied to the entire VAF spectrum of subclonal mutations only. Moreover, we have recently developed a Bayesian model selection framework that compares the neutral model against models with selection, using the entire VAF distribution 3 . We do stress, however, that most cancers analyzed in our original manuscript were not neutral and showed signs of subclonal selection.
interpretation of the 1/f statistical test
Tarabichi and colleagues correctly note that failing to reject the null is not necessarily evidence for it. Although this statement is true, hypothesis-driven evolutionary analysis of cancer genomic data requires a sensible null. Analyzing data without knowing what to expect in the simplest scenarios may lead to incorrect conclusions, as we have highlighted 4 . We have proposed neutrality, the null model of molecular evolution 5 , as a sufficient explanation of the available data from a proportion of . c, Example VAF distribution with a weakly selected subclone that remains below the limit of detection (100× depth). d, Subclone cell fraction in the final tumor as a function of fitness advantage; for adv subclone < 0.5, the subclone rarely reaches a detectable size of ~10% cell fraction (assuming 100× depth). LOD, limit of detectability. e, Example VAF distribution for a subclone with a selective advantage and, at the same time, a high mutation rate. f, Example VAF distribution for a selected and extreme mutator subclone. g, Sensitivity of the 1/f test applied to subclonal mutations in the extended range of VAF = [0.025,0.45] from the simulations in a. Numbers report the proportion of cases in which neutrality was rejected (R 2 < 0.98). h, Sensitivity of subclone detection of DPclust, a Dirichlet subclonal clustering method, applied to the same simulated data. Numbers report the proportion of cases (20 cases per combination) for which the correct subclone was identified within a 5% cancer cell fraction (CCF) error with respect to true position.
tumors. The test that we applied quantifies the deviation from the null distribution in terms of a change in the model parameter (s = 0 versus s > 0). This structure arises from a frequentist approach, and arguments for setting up the test in any other way are arbitrary and impractical. There are an infinite number of models of selection; some produce vanishingly small and thus unmeasurable deviations from neutrality (i.e., weak selection), whereas others are biologically unrealistic (for example, every mutation is a driver, or constant population size in cancer). This is why neutrality is a suitable null 5 in molecular evolution. In our view, selection is arguably the most important force in cancer, but a sensible null model avoids overinterpretation of data.
Tarabichi and colleagues state that the M(f) ~1/f deterministic solution reported in equation (7) in our manuscript relies on the strong assumption of synchronous cell divisions. However, that is not the case: equation (7) ), thus demonstrating the convergence to the deterministic solution. A comprehensive analysis of the underlying stochastic Luria-Delbrück model shows that the scaling behavior of the stochastic branching process (1/f tail) remains unchanged even in the explicit presence of stochastic cell death 7 . In Tarabichi's Fig. 1b , the claim that a stochastic neutral model does not imply 1/f is therefore incorrect, as has also been demonstrated by others before us [6] [7] [8] . Moreover, Tarabichi and colleagues argue that the 1/f tail is due solely to drift. That conclusion is true only in populations of constant size. In exponentially growing populations that start from a single cell, such as cancer, the 1/f subclonal tail emerges instead from somatic mutations acquired at different times during growth.
insights from simulated tumors
Tarabichi and colleagues have used a stochastic branching process, similar to our previous implementation 2, 3 , to generate synthetic genomic data and test our method. In their . The parameters used in Tarabichi's simulations are also rather extreme. In their model, the emergence of a subclonal driver increases the net growth rate (adv subclone , selective advantage) and simultaneously modifies the mutation rate. Curiously, the mutation rate can decrease by a factor of 8 or increase by a factor of 100. A rate of 1,024 new mutations per cell division (Tarabichi's Fig. 1a , x axis, µ subclone = 2 10 ) pertains only to a very small set of colorectal and uterine cancers with POLE/POLD alterations. A POLE subclone arising within a POLE wild-type background is an extremely rare event 10 . Thus, we urge caution when considering the implications of the parameters at the extremities of the range considered by Tarabichi et al.
To address the authors' criticism, we have reproduced Tarabichi (Fig. 1d) , thus highlighting the issue of the limit of detectability. We previously quantified this effect 3 , identifying a 'wedge of selection' that describes the detectability problem in cancer genomic data at current resolution. If subclonal selection does not significantly change the clonal composition of the tumor, the signature of neutral growth ('1/f tail') will still dominate the detectable VAF spectrum (bottom part of Fig. 1a) .
Notably, for a hypermutant subclone with strong selective advantage (µ subclone ≥ 64, top right of Fig. 1a) , the analysis shows a massive 1/f tail containing thousands of the subclone's private mutations. These mutations dominate the entire VAF distribution and obscure the underlying subclonal structure ( Fig. 1a ; example in Fig. 1e) . Unsurprisingly, our test, or any other test, would struggle to detect any subclonal cluster or deviation from 1/f in these cases. Curiously, for moderate values of selection (adv subclone ~0.5), a change in mutation rate from normal to hypermutant could be detected, thus leading to rejection of neutrality (mid-right area in Fig. 1a ; example in Fig. 1f ; additional data in Supplementary Fig. 11h in ref. 2 ). For weak selection and a hypermutator subclone, the new subclone did not reach a detectable size, and therefore neutrality was not rejected (Fig. 1c) .
Importantly, we note that the lack of discriminatory power in these peculiar scenarios does not depend on our method, but it is largely due to minimal signal in the data. To demonstrate this, we compared our method applied to the extended integration range (Fig. 1g) to DPclust, a method to detect subclones on the basis of Dirichlet Process clustering 11 proposed by some of the authors of this Correspondence (Supplementary Methods). Even under optimal circumstances (strong selection), the sensitivity of DPclust is suboptimal in most cases (Fig. 1h) .
We are pleased, however, that Tarabichi and colleagues confirmed that 1/f tails are pervasive in cancer genomic data. Neutral tails are a simple consequence of clonal growth and appear within each individual clone during its expansion 2, 3 .
Analysis of subclonal selection by using dN/dS ratios
Using a test inspired by the classical dN/dS method, Tarabichi et al. argue that they have found evidence of subclonal selection in tumors classified by our test as neutral. Specifically, the authors pooled subclonal mutations in known cancer genes from multiple patients and calculated a dN/dS value for neutral and non-neutral groups. Their criticism is that subclonal mutations in the neutral group should lack evidence of selection (dN/dS ~1).
First, we note that it is incorrect to draw conclusions about individual samples from such a population-level statistic. Instead, discrepancies between the dN/dS value and our 1/f test results could simply mean that our method may have misclassified one or more patients. To investigate this possibility, we reproduced Tarabichi's analysis by using the same dN/dS method 12 and measured global dN/dS for 369 driver genes 12 in colorectal and gastric cancers analyzed in our original manuscript 2 . Because Tarabichi's TCGA pancancer analysis used CAVEMAN calls that are not publicly available, we instead reanalyzed the pancancer TCGA variant calls publicly available from the GDC data portal (Supplementary Methods). We found that in all three cohorts, the dN/dS of subclonal missense mutations in neutral-classified tumors was not significantly different from 1, thus confirming our findings (Fig. 2a-c , missense mutations at left, blue bars).
Interestingly, we found a small group of neutrally classified patients with an unusually high number of subclonal nonsense mutations in putative driver genes. Among gastric cancers, 1/57 cases (1.7%) and 11/290 (3.8%) pancancer cases had three or more subclonal nonsense mutations. We manually examined these patients ( Supplementary Fig. 2 ) and found that they were affected by clonal mutations 'bleeding' into the subclonal integration range, a misclassification caused by ploidy measurement errors and possibly the presence of selected subclones hidden underneath 1/f tails. We stress that these tumors had been classified with our original limited integration range. After removal of patients with three or more nonsense mutations (i.e., leaving 96.2% of putatively neutral cases in the pancancer cohort), the dN/dS value for nonsense was not significantly different from that of the neutral background ( Fig. 2c ; dN/dS = 1.44, P = 0.32). We demonstrated this by generating dN/dS values for 'control sets' (background) of passenger genes by using bootstrapping of 1,000 random sets of 198 nondriver genes 13 as well as neutral genes from Martincorena et al. 12 and Zapata et al. 15 ( Fig. 2d) . This analysis indicates a systematic positive bias for the estimation of dN/dS, possibly as a result of public GDC calls being depleted of synonymous somatic mutations present in dbSNP, thus skewing dN/dS values, as mentioned in ref. 12 . Consistently with our study, the subclonal dN/dS values were consistently higher in non-neutral versus neutral cases, although this result was not significant (Fig. 2d) .
We highlight that dN/dS analysis at the cohort level combines mutations from different patients, whereas the neutrality test is patient specific. Even a single misclassified patient carrying multiple nonsense mutations in driver genes can significantly alter the dN/dS value of a whole cohort. While dN/dS can identify an excess or depletion of mutations in a cohort, the analysis by Tarabichi et al. cannot differentiate whether such a result comes from one or multiple patients.
summary
We thank Tarabichi and colleagues for providing some valid constructive criticism of our original manuscript. In our assessment of their critique, however, our original conclusion remains valid: that neutral evolution provides an entirely adequate description of the pattern of intratumor heterogeneity that has been observed to date across many tumors. We are also grateful to Tarabichi and coauthors because they led us to the finding that VAF-distribution analyses applied to single patients, such as our neutrality test, can be carefully combined with cohort-level statistics such as dN/dS to increase the 14 analyzed in ref.
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. b, TCGA pancancer cases analyzed by using newly available GDC calls to reproduce Tarabichi's dN/dS analysis. c, Cancers were classified as neutral or non-neutral with the 1/f test, and the dN/dS values of were calculated over pooled variants from each group (split between clonal/subclonal and missense/nonsense). d, Comparison of the dN/dS estimates obtained for the 198 driver genes (black dots, point estimates; error bars, 95% CI) with the distribution of 1,000 random subsets from three control sets of nondriver genes, demonstrating a general positive bias of estimated dN/dS values (white dots, median; box, interquartile range; whiskers, 90% prediction interval). After removal of 3.8% of pancancer cases with three or more subclonal nonsense mutations in driver genes, both missense and nonsense dN/dS in neutral cancers were not significantly different from the neutral expectation. 'Martincorena' refers to ref. 12 , 'Zapata' refers to ref. 15 .
Reply to 'No evidence for unknown archaic ancestry in South Asia'
Mondal et al. reply -In a 2016 paper 1 , we derived three main conclusions: (i) that all Asian and Pacific populations share a single origin and expansion out of Africa; (ii) that populations from South and Southeast Asia harbor a small proportion of ancestry from an unknown extinct hominin different from the Neanderthal and the Denisova; and (iii) that the distinctive characteristic of short stature in the Andamanese has resulted from strong positive selection on genes related to body size. The existence of admixture with an extinct hominin has been challenged by Skoglund et al. 2 , who have not been able to replicate our results in other datasets and have alleged that our statistical treatment of the data was improper, pointing out some possible sources of error.
Here, we (i) replicated our results in independent datasets; (ii) reexamined our data with a focus on possible sources of error, such as the number of individuals, differences in coverage and batch effects; and (iii) performed new statistical analysis to detect introgressed regions in the Andamanese and confirm their unknown origin. The new analyses both bolstered our confidence that our earlier inferences were correct and resulted in an improved model of introgression of modern humans with a hitherto-unknown archaic ancestry.
Analysis using data from the sGDP dataset
We downloaded sequences from the 1000 Genomes Project (KGP) 3 Analysis used data from the KGP, the SGDP and some high-coverage extinct archaic genomes mapped on the chimpanzee (chimp) reference 5 : two Europeans (EUR; British in England and Scotland (GBR) and CEU), two East Asians (ASN; Han Chinese in Beijing, China (CHB) and Japanese in Tokyo, Japan (JPT)), two Africans (AFR; YRI), two Irulas (ILA)), two Pacific populations (PAC; Papuan, Australian Aborigines), two Neanderthals (NEAN; Altai and Vindija) and one Denisova (DENI). Chimpanzee alleles are the reference alleles from the pantro4 pan-troglodyte assembly.
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